Maurie Markman, MD


May 23, 2013

This feature requires the newest version of Flash. You can download it here.

Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I want to briefly highlight several of the abstracts that will be appearing at the American Society of Clinical Oncology (ASCO®) meeting this year, dealing with the management of gynecologic malignancies. Two of the abstracts in the plenary session of ASCO will deal with cervix cancer, an unusual event.

The first abstract[1] deals with the clinical value of adding bevacizumab to combination chemotherapy in the management of recurrent metastatic cervix cancer. The second abstract[2] deals with a novel screening strategy for cervix cancer, conducted in Mumbai, India. This should be a very interesting presentation, because cervix cancer is truly a major health issue in the developing world.

Another abstract[3] deals with a phase 3 randomized trial looking at weekly vs every-3-weeks paclitaxel, given in combination, in the management of ovarian cancer. This is a European trial and it will be very important to see the results of this study and to see how these results compare with the previously reported, very impressive data that came from a Japanese study,[4] showing that weekly paclitaxel was associated with a superior progression-free and overall survival outcome.

A very important study, known as the CHORUS trial,[5] is being reported. This trial looked at the use of neoadjuvant chemotherapy in the management of advanced ovarian cancer. This study, at least according to the abstract, again demonstrates the value of neoadjuvant chemotherapy. In fact, 12-month survival was superior, although it was not stated to be statistically significantly superior to the use of surgery as a primary modality in the management of advanced cervix cancer.

A follow-up report[6] on the use of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer will be presented. This study looked specifically at the population that was documented to be BRCA mutation carriers. The improvement in median progression-free survival (which was 4.1 months in the maintenance strategy with placebo in the BRCA carriers) increased to a median of 11.2 months with the use of olaparib. This is a very interesting observation.

Finally, we will be hearing the results of a randomized, double-blind phase 3 study[7] that looked at pazopanib vs placebo as a maintenance strategy in advanced ovarian cancer after first-line chemotherapy. This study has been awaited with great interest.

These are just the highlights of a few of the abstracts. Clearly, this is going to be a very interesting year for gynecologic cancer abstracts, at the plenary session, the oral abstract session, the poster discussion section, and in the very large poster session. I would encourage all of you who have an interest in the area of gynecologic malignancies to attend and participate in the presentations, as well as the discussions to follow.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: